The annual ESTRO meeting (ESTRO37) took place in Barcelona April 21.-24. The meeting hosted more than 6000 participants - the largest attendance to annual ESTRO meetings so far. We were happy, that we could make new data and research from EMBRACE available to our ESTRO colleagues through many presentations during the meeting. The presentations reflected our work on outcome (disease and morbidity), QA and monitoring, education as well as treatment related parameters. Simon Duke (Cambridge University Hospital) has been very active in the development and evaluation of the EMBRACE educational programme, and he won a poster award for his work on this. Congratulations to Simon.

During the ESTRO meeting, the EMBRACE/GEC ESTRO gyn network group also held an open meeting. More than 30 colleagues participated to hear news on EMBRACE, GEC ESTRO gyn task groups (vagina, endometrium) and the recently published ESTRO/ESGO/ESP guidelines.


These were the ESTRO37 contributions from EMBRACE (abstracts can be found on the ESTRO website):


Li Tee Tan: Impact of image-guided brachytherapy on pattern of relapse in the RetroEMBRACE cervix cancer study


Lars Fokdal: Risk factors for ureteral stricture following image guided adaptive brachytherapy in cervical cancer: results from the EMBRACE studies


Nicole Nesvacil: Implementation of IGBT for cervix cancer in the observational multicenter study EMBRACEMonica


Simon Duke: Implementing a novel online education programme to support RTQA – the EMBRACE-II experience


Serban: Isodose surface volume in cervix brachytherapy: dependence on image guided adaptation and applicator


Thomas Berger: Evolution of external beam radiotherapy in cervix cancer: from EMBRACE I to EMBRACE II


Kari Tanderup: Late, persistent, substantial, treatment-related symptoms (LAPERS): a new metric for late effects


Already 500 patients!

So many new patients despite summer time

400 patients enrolled in EMBRACE II

A new milestone has been reached